Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.
The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.
Sandy Srinivas, MD, discusses the therapeutic landscape of mCRPC and the need to develop novel treatment options.
The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.
Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.
Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.
The frontline combination of obinutuzumab and zanubrutinib demonstrated efficacy and safety in older patients with mantle cell lymphoma.
R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.
Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.
Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.
